Figure 3.
PD-L1 expression on monocyte/macrophages in cHL and DLBCL. (A) Proportion of circulating PD-L1+CD163+CD14+ monocytes in the pretherapy blood of cHL and DLBCL patients and healthy participants. (B) Mean fluorescent intensity of PD-L1 on CD163+CD14+ monocytes in the pretherapy blood of cHL relative to DLBCL and healthy participants. (C) Gene expression by nanoString nCounter in cHL and DLBCL patient lymph nodes. (D) Representative images of multispectral microscopic visualization of PD-L1 (cyan), CD163 (yellow), CD20, or CD30 (magenta) from cHL and DLBCL diseased lymph nodes, with 4′,6-diamidino-2-phenylindole (dark blue) as the nuclear marker. (E) Representative fluorescence-activated cell sorter plots from cHL and DLBCL lymphomatous nodes of PD-L1/PD-L2 on CD163+CD14+ monocytes/macrophages.

PD-L1 expression on monocyte/macrophages in cHL and DLBCL. (A) Proportion of circulating PD-L1+CD163+CD14+ monocytes in the pretherapy blood of cHL and DLBCL patients and healthy participants. (B) Mean fluorescent intensity of PD-L1 on CD163+CD14+ monocytes in the pretherapy blood of cHL relative to DLBCL and healthy participants. (C) Gene expression by nanoString nCounter in cHL and DLBCL patient lymph nodes. (D) Representative images of multispectral microscopic visualization of PD-L1 (cyan), CD163 (yellow), CD20, or CD30 (magenta) from cHL and DLBCL diseased lymph nodes, with 4′,6-diamidino-2-phenylindole (dark blue) as the nuclear marker. (E) Representative fluorescence-activated cell sorter plots from cHL and DLBCL lymphomatous nodes of PD-L1/PD-L2 on CD163+CD14+ monocytes/macrophages.

Close Modal

or Create an Account

Close Modal
Close Modal